

MEDICURE INC  
Form 6-K  
November 07, 2005

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **November, 2005**

Commission File Number: **001-31995**

**MEDICURE INC.**

(Translation of registrant's name into English)

**4-1200 Waverley Street  
Winnipeg, MB Canada R3T 0P4**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F     Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**SUBMITTED HEREWITH**

Exhibits

99.1 Press Release Dated October 24, 2005 - Medicure to Webcast 2005 Annual and Special Meeting

99.2 Press Release Dated November 3, 2005 - Medicure to Present at Biotech Investor Conference

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Medicure Inc.**  
(Registrant)

Date: November 4, 2005

By: */s/ Dr. Albert D. Friesen*

\_\_\_\_\_  
Dr. Albert D. Friesen  
Title: President & CEO

---